TriangleNCT01721772 · OUTCOME
Overall Survival (OS) Rate
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From randomization to 6 months and or to 12 months
What was measured
OS rate is calculated as the percentage of participants alive at the indicated timepoints
Analysis population: All randomized participants
Groups in this outcome
Nivolumab, 3 mg/kg + Placebo-matching Dacarbazine
Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks with placebo-matching dacarbazine solution administered IV every 3 weeks, until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion
Dacarbazine, 1000 mg/m^2 + Placebo-matching Nivolumab
Participants received dacarbazine 1000 mg/m\^2, solution administered IV every 3 weeks with placebo-matching nivolumab solution administered IV every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion
| Group | Source count |
|---|---|
| Nivolumab, 3 mg/kg + Placebo-matching Dacarbazine | 210 |
| Dacarbazine, 1000 mg/m^2 + Placebo-matching Nivolumab | 208 |
Reported measurements
At 6 months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Nivolumab, 3 mg/kg + Placebo-matching Dacarbazine | 84.1 | Not reported | 78.3 | 88.5 | Not reported |
| Dacarbazine, 1000 mg/m^2 + Placebo-matching Nivolumab | 71.8 | Not reported | 64.9 | 77.6 | Not reported |
At 12 months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Nivolumab, 3 mg/kg + Placebo-matching Dacarbazine | 72.9 | Not reported | 65.5 | 78.9 | Not reported |
| Dacarbazine, 1000 mg/m^2 + Placebo-matching Nivolumab | 42.1 | Not reported | 33.0 | 50.9 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 78.3
- upper Limit
- 88.5
- value
- 84.1
- group Id
- OG001
- lower Limit
- 64.9
- upper Limit
- 77.6
- value
- 71.8
- title
- At 6 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 65.5
- upper Limit
- 78.9
- value
- 72.9
- group Id
- OG001
- lower Limit
- 33.0
- upper Limit
- 50.9
- value
- 42.1
- title
- At 12 months
- denoms
- counts
- group Id
- OG000
- value
- 210
- group Id
- OG001
- value
- 208
- units
- Participants
- description
- OS rate is calculated as the percentage of participants alive at the indicated timepoints
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks with placebo-matching dacarbazine solution administered IV every 3 weeks, until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion
- id
- OG000
- title
- Nivolumab, 3 mg/kg + Placebo-matching Dacarbazine
- description
- Participants received dacarbazine 1000 mg/m\^2, solution administered IV every 3 weeks with placebo-matching nivolumab solution administered IV every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion
- id
- OG001
- title
- Dacarbazine, 1000 mg/m^2 + Placebo-matching Nivolumab
- param Type
- NUMBER
- population Description
- All randomized participants
- reporting Status
- POSTED
- time Frame
- From randomization to 6 months and or to 12 months
- title
- Overall Survival (OS) Rate
- type
- PRIMARY
- unit Of Measure
- Percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice